Tobira Therapeutics Company Profile (NASDAQ:TBRA)

About Tobira Therapeutics

Tobira Therapeutics logoTobira Therapeutics, Inc., formerly Regado Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company's lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV. The Company's CVC product candidate is an oral, once-daily immunomodulator that blocks the chemokine receptors, CCR2 and CCR5, which are involved in the inflammatory and fibrogenic pathways in NASH and PSC that cause liver damage, and can lead to cirrhosis, liver cancer or liver failure. It is conducting a global Phase IIb study evaluating CVC in NASH patients with liver fibrosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: TBRA
  • CUSIP:
Key Metrics:
  • Previous Close: $39.95
  • 50 Day Moving Average: $9.62
  • 200 Day Moving Average: $9.17
  • 52-Week Range: $3.76 - $41.39
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -15.85
  • P/E Growth: 0.32
  • Market Cap: $751.90M
  • Outstanding Shares: 18,821,000
  • Beta: -0.54
Profitability:
  • Return on Equity: -109.45%
  • Return on Assets: -71.32%
Debt:
  • Debt-to-Equity Ratio: 0.44%
  • Current Ratio: 5.38%
  • Quick Ratio: 5.38%
Additional Links:
Companies Related to Tobira Therapeutics:

Analyst Ratings

Consensus Ratings for Tobira Therapeutics (NASDAQ:TBRA) (?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $81.40 (103.75% upside)

Analysts' Ratings History for Tobira Therapeutics (NASDAQ:TBRA)
Show:
DateFirmActionRatingPrice TargetDetails
9/22/2016MizuhoReiterated RatingBuy$305.00View Rating Details
9/21/2016Cantor FitzgeraldDowngradeBuy -> Hold$19.00 -> $42.00View Rating Details
8/13/2016HC WainwrightReiterated RatingBuy$22.00 -> $31.00View Rating Details
8/10/2016Cowen and CompanyReiterated RatingBuy$11.00View Rating Details
5/10/2016Leerink SwannReiterated RatingBuy$18.00View Rating Details
2/22/2015WedbushReiterated RatingUnderperform$1.00View Rating Details
11/6/2014Jefferies GroupReiterated RatingHold$1.50 -> $1.00View Rating Details
(Data available from 9/27/2014 forward)

Earnings

Earnings History for Tobira Therapeutics (NASDAQ:TBRA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2016        
8/9/2016Q216($0.63)($0.71)$1.06 millionViewN/AView Earnings Details
5/9/2016Q116($0.53)($0.65)ViewN/AView Earnings Details
3/3/2016Q415($0.52)($0.50)ViewN/AView Earnings Details
11/10/2015Q315($1.00)($1.22)ViewListenView Earnings Details
8/11/2015Q215($0.99)ViewListenView Earnings Details
11/6/2014Q314($0.45)($0.59)ViewN/AView Earnings Details
8/11/2014Q214($0.51)($0.63)ViewN/AView Earnings Details
5/14/2014Q114($0.62)($1.30)ViewN/AView Earnings Details
11/7/2013($0.43)($1.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Tobira Therapeutics (NASDAQ:TBRA)
Current Year EPS Consensus Estimate: $-2.65 EPS
Next Year EPS Consensus Estimate: $-2.52 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($0.69)($0.69)($0.69)
Q4 20161($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Tobira Therapeutics (NASDAQ:TBRA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Tobira Therapeutics (NASDAQ:TBRA)
Insider Ownership Percentage: 6.20%
Institutional Ownership Percentage: 62.02%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Pentwater Capital Management LMajor ShareholderBuy100,000$39.19$3,919,000.00View SEC Filing  
9/22/2016Pentwater Capital Management LMajor ShareholderBuy1,624,200$39.04$63,408,768.00View SEC Filing  
7/13/2016A/S NovoMajor ShareholderSell59,067$12.02$709,985.34View SEC Filing  
7/7/2016A/S NovoMajor ShareholderSell92,119$12.20$1,123,851.80View SEC Filing  
6/30/2016A/S NovoMajor ShareholderSell66,814$13.04$871,254.56View SEC Filing  
6/6/2016A/S NovoMajor ShareholderSell187,500$10.37$1,944,375.00View SEC Filing  
3/4/2016A/S NovoMajor ShareholderSell190,000$6.80$1,292,000.00View SEC Filing  
11/18/2015A/S Novomajor shareholderSell225,000$9.79$2,202,750.00View SEC Filing  
5/4/2015A/S NovoMajor ShareholderBuy838,041$10.62$8,899,995.42View SEC Filing  
5/4/2015Parters Vii L P DomainMajor ShareholderBuy277,777$10.62$2,949,991.74View SEC Filing  
4/16/2014Robert Kierlinmajor shareholderBuy575,000$6.00$3,450,000.00View SEC Filing  
2/5/2014Robert Kierlinmajor shareholderBuy400,000$5.00$2,000,000.00View SEC Filing  
8/27/2013Raphael WisniewskiDirectorBuy1,215,708$4.00$4,862,832.00View SEC Filing  
8/27/2013Rmi Investments S.A.R.L.Major ShareholderBuy3,866,529$4.00$15,466,116.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Tobira Therapeutics (NASDAQ:TBRA)
DateHeadline
investornewswire.com logoCan Shares Of Tobira Therapeutics, Inc. (NASDAQ:TBRA) Hit $31? - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - September 27 at 7:32 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Tobira … (NASDAQ:TBRA)
finance.yahoo.com - September 26 at 7:38 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share is Fair to Shareholders -- TBRA (NASDAQ:TBRA)
finance.yahoo.com - September 26 at 7:38 PM
4-traders.com logoAcquisition of Tobira Therapeutics Inc (NASDAQ:TBRA) Under Investigation for Investors (NASDAQ:TBRA)
www.4-traders.com - September 26 at 11:42 AM
finance.yahoo.com logoAllergan Gets FDA Approval for New Line of Breast Implants (NASDAQ:TBRA)
finance.yahoo.com - September 26 at 11:42 AM
finance.yahoo.com logoThe Zacks Analyst Blog Highlights: Deutsche Bank, Apple, Therapeutics, Allergan and Gilead Sciences (NASDAQ:TBRA)
finance.yahoo.com - September 26 at 11:42 AM
insidermonkey.com logoTobira Therapeutics Inc. (TBRA): Pentwater Capital Management Reports New Position (NASDAQ:TBRA)
www.insidermonkey.com - September 24 at 6:48 PM
prnewswire.com logoTOBIRA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Tobira Therapeutics, Inc ... - PR Newswire (press release) (NASDAQ:TBRA)
www.prnewswire.com - September 23 at 6:58 PM
insidermonkey.com logoTobira Therapeutics Inc. (TBRA): Pentwater Capital Management Reports New Position - Insider Monkey (blog) (NASDAQ:TBRA)
www.insidermonkey.com - September 23 at 6:58 PM
News IconChanges To Tobira Therapeutics, Inc. (TBRA) Target Prices (NASDAQ:TBRA)
larampadinapoli.com - September 23 at 10:23 AM
finance.yahoo.com logoAllergan/Adamas Launch New Dosage Strengths of Namzaric (NASDAQ:TBRA)
finance.yahoo.com - September 23 at 10:23 AM
News IconStocks Skyrockets on Unusual Volume: Primoris Services (NASDAQ:PRIM), Tobira Therapeutics (TBRA), Gold ... - Street Wise Report (press release) (blog) (NASDAQ:TBRA)
streetwisereport.com - September 22 at 7:15 PM
finance.yahoo.com logoIs Galectin The Next Takeover Target for the Biotech World? (NASDAQ:TBRA)
finance.yahoo.com - September 22 at 10:31 AM
News IconTobira Therapeutics Inc (NASDAQ:TBRA) & Allergan plc Ordinary Shares (NYSE:AGN) Stocks to Keep Your Eyes on (NASDAQ:TBRA)
www.newsismoney.com - September 21 at 7:05 PM
thestreet.com logoAllergan's Boldness may not be Limited to Tobira Deal (NASDAQ:TBRA)
www.thestreet.com - September 21 at 7:05 PM
cnbc.com logoAllergan CEO says 'the American people deserve to be angry' at price gouging (NASDAQ:TBRA)
www.cnbc.com - September 21 at 7:05 PM
finance.yahoo.com logoWhy Did Tobira Therapeutics (TBRA) Stock Skyrocket 720% Today? (NASDAQ:TBRA)
finance.yahoo.com - September 21 at 11:44 AM
News IconSarepta Therapeutics Inc (NASDAQ:SRPT), Tobira Therapeutics Inc (NASDAQ:TBRA) Are Our Stocks of The Week At Traders Insights (NASDAQ:TBRA)
www.marketnewscall.com - September 21 at 11:43 AM
News IconStock Perspective: Tobira Therapeutics, Inc. (NASDAQ:TBRA) Earnings in View - Frisco Fastball (NASDAQ:TBRA)
friscofastball.com - September 21 at 11:43 AM
rttnews.com logoTobira Therapeutics Inc. (TBRA) Vaulted To A New High After Bought By Allergan (NASDAQ:TBRA)
www.rttnews.com - September 21 at 11:43 AM
News IconVolatile Stock to Watch - Tobira Therapeutics, Inc.'s (TBRA) - Hot Stocks Point (NASDAQ:TBRA)
www.hotstockspoint.com - September 21 at 11:43 AM
investorplace.com logoWhy DTS Inc. (DTSI), FedEx Corporation (FDX), and Tobira Therapeutics Inc (TBRA) Are 3 of Today's Best Stocks - Investorplace.com (NASDAQ:TBRA)
investorplace.com - September 21 at 11:43 AM
finance.yahoo.com logoHarwood Feffer LLP Announces Investigation of Tobira Therapeutics, Inc. (NASDAQ:TBRA)
finance.yahoo.com - September 21 at 11:43 AM
finance.yahoo.com logoHarwood Feffer LLP Announces Investigation of Tobira Therapeutics, Inc. (NASDAQ:TBRA)
finance.yahoo.com - September 21 at 11:43 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders (NASDAQ:TBRA)
finance.yahoo.com - September 21 at 11:43 AM
finance.yahoo.com logoINVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into Whether the Sale of Tobira Therapeutics, Inc. to Allergan plc for $28.35 Per Share Is Fair to Shareholders (NASDAQ:TBRA)
finance.yahoo.com - September 21 at 11:43 AM
investorplace.com logoWhy DTS Inc. (DTSI), FedEx Corporation (FDX), and Tobira Therapeutics Inc (TBRA) Are 3 of Today’s Best Stocks (NASDAQ:TBRA)
investorplace.com - September 20 at 5:46 PM
schaeffersresearch.com logoDow Jones Industrial Average Futures Jump Ahead of Fed Meeting - Schaeffers Research (blog) (NASDAQ:TBRA)
www.schaeffersresearch.com - September 20 at 9:41 AM
streetinsider.com logoAllergan (AGN) to Acquire Tobira Therapeutics (TBRA) for $28.35/Share in Cash and up to $49.84 in CVRs - StreetInsider.com (NASDAQ:TBRA)
www.streetinsider.com - September 20 at 9:41 AM
thestreet.com logoStocks Rise as Federal Reserve Meeting Begins (NASDAQ:TBRA)
www.thestreet.com - September 20 at 9:41 AM
News IconStock Update: Estimates & Target in Focus for Tobira Therapeutics, Inc. (NASDAQ:TBRA) - Frisco Fastball (NASDAQ:TBRA)
friscofastball.com - September 14 at 11:57 AM
investornewswire.com logoCan Shares Of Tobira Therapeutics, Inc. (NASDAQ:TBRA) Hit $31 - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - September 14 at 11:57 AM
streetinsider.com logoTobira Therapeutics (TBRA) Begins Phase 1 Combination Study of Cenicriviroc and Evogliptin - StreetInsider.com (NASDAQ:TBRA)
www.streetinsider.com - September 14 at 11:57 AM
streetinsider.com logoTobira Therapeutics (TBRA) Begins Phase 1 Combination Study of Cenicriviroc and Evogliptin (NASDAQ:TBRA)
www.streetinsider.com - September 13 at 10:43 AM
finance.yahoo.com logo8:01 am Tobira Therapeutics initiates a Phase 1 study of cenicriviroc in combination with evogliptin (NASDAQ:TBRA)
finance.yahoo.com - September 12 at 10:37 AM
publicnow.com logoTobira Therapeutics Announces Initiation of Phase 1 Combination Study of Cenicriviroc and Evogliptin (NASDAQ:TBRA)
www.publicnow.com - September 12 at 10:36 AM
businesswire.com logoTobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering ... - Business Wire (press release) (NASDAQ:TBRA)
www.businesswire.com - September 7 at 7:44 PM
publicnow.com logoTobira Therapeutics Announces Appointment of Dr. Laurent Fischer as Industry Co-chair of the Liver Forum Steering Committee (NASDAQ:TBRA)
www.publicnow.com - September 7 at 11:22 AM
News IconTobira To Participate In Two Conferences In September (NASDAQ:TBRA)
www.biospace.com - September 2 at 7:29 PM
finance.yahoo.com logoTobira Therapeutics to Participate in Two Conferences in September (NASDAQ:TBRA)
finance.yahoo.com - September 1 at 7:35 PM
investornewswire.com logoWill Tobira Therapeutics, Inc. (NASDAQ:TBRA) Hit $31 Price Target? - Investor Newswire (NASDAQ:TBRA)
www.investornewswire.com - August 18 at 10:47 AM
News IconBiotech news that matter for investors: Tobira Therapeutics, Inc. (TBRA), Celldex Therapeutics, Inc. (CLDX) - The Voice Registrar (NASDAQ:TBRA)
voiceregistrar.com - August 16 at 11:01 AM
investing.com logoTobira Therapeutics Inc Broke Out Of A Bottom Pattern (NASDAQ:TBRA)
www.investing.com - August 15 at 9:51 AM
News IconInvestor News: Tobira Therapeutics Inc (NASDAQ:TBRA) faces Investigation over possible Violations of Securities Laws (NASDAQ:TBRA)
www.groundreport.com - August 15 at 9:50 AM
News IconAnalysts Review on Trending Stock: Tobira Therapeutics Inc (NASDAQ:TBRA) - Post Registrar (NASDAQ:TBRA)
postregistrar.com - August 13 at 10:31 AM
News IconAnalysts Review: Tobira Therapeutics, Inc. (NASDAQ:TBRA) | | Post ... - Post Registrar (NASDAQ:TBRA)
postregistrar.com - August 11 at 8:17 PM
News IconTobira Reports Second Quarter 2016 Financial And Business Results (NASDAQ:TBRA)
www.biospace.com - August 10 at 8:15 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tobira Therapeutics, Inc. (TBRA) (NASDAQ:TBRA)
finance.yahoo.com - August 10 at 10:52 AM
sg.finance.yahoo.com logoTobira reports 2Q loss (NASDAQ:TBRA)
sg.finance.yahoo.com - August 9 at 8:01 PM
biz.yahoo.com logoTOBIRA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and (NASDAQ:TBRA)
biz.yahoo.com - August 9 at 8:01 PM

Social

Tobira Therapeutics (NASDAQ:TBRA) Chart for Tuesday, September, 27, 2016


Last Updated on 9/27/2016 by MarketBeat.com Staff